Precision therapeutic strategies based on molecular typing of NPR family, such as anti-angiogenic combination therapy for gastric cancer patients with upregulated levels of NPRA; 5 to validate the feasibility of NPR family as a liquid biopsy marker, such as detection of seminal plasma NT-proCNP level for dynamic monitoring of prostate cancer; 6 to focus on the functions of receptor heterodimerization and shear variants and elucidate their roles in tumor heterogeneity. The gene discussed is NPTXR; the disease is prostate carcinoma.